Literature DB >> 1804734

Colonic mucosal interleukin-6 in inflammatory bowel disease.

K Mitsuyama1, E Sasaki, A Toyonaga, H Ikeda, O Tsuruta, A Irie, N Arima, T Oriishi, K Harada, K Fujisaki.   

Abstract

Interleukin-6, a cytokine produced by various cell types, has a major role in inflammatory and immunological reactions. To define its potential role in inflammatory bowel disease, its concentrations in endoscopic biopsy samples from patients with ulcerative colitis and Crohn's disease were measured. The involved colonic mucosa from active disease was found to contain significantly larger amounts of interleukin-6 than that from inactive disease or normal controls. Colonic mucosal interleukin-6 levels correlated well with the grade of macroscopic inflammation, especially in patients with ulcerative colitis. The levels of interleukin-6 decreased in parallel with clinical improvement following the start of therapy in patients with both forms of inflammatory bowel disease. Mucosal interleukin-6 is thus concluded to accurately reflect the degree of colonic inflammation and may be importantly associated with inflammatory and immunological phenomena seen in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804734     DOI: 10.1159/000200747

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  33 in total

1.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.

Authors:  K Mitsuyama; S Matsumoto; S Rose-John; A Suzuki; T Hara; N Tomiyasu; K Handa; O Tsuruta; H Funabashi; J Scheller; A Toyonaga; M Sata
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 3.  Nematodes and human therapeutic trials for inflammatory disease.

Authors:  D E Elliott; J V Weinstock
Journal:  Parasite Immunol       Date:  2017-04-18       Impact factor: 2.280

4.  In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Authors:  J M Reimund; S Dumont; C D Muller; J S Kenney; M Kedinger; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

5.  Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis.

Authors:  K Mitsuyama; A Suzuki; S Matsumoto; N Tomiyasu; K Takaki; H Takedatsu; J Masuda; K Handa; K Harada; H Nishida; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

7.  Persistence of local cytokine production in shigellosis in acute and convalescent stages.

Authors:  R Raqib; A A Lindberg; B Wretlind; P K Bardhan; U Andersson; J Andersson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line.

Authors:  D W McGee; T Bamberg; S J Vitkus; J R McGhee
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 9.  Colitis-associated cancer: the role of T cells in tumor development.

Authors:  Maximilian J Waldner; Markus F Neurath
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

10.  Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.

Authors:  K Mitsuyama; A Toyonaga; E Sasaki; O Ishida; H Ikeda; O Tsuruta; K Harada; H Tateishi; T Nishiyama; K Tanikawa
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.